Skip to main content
Livermore
Livermore
ZHEN

Sio Capital Management, LLC

SEC CIK
0001482416
Latest filing
Aug 14, 2026

The latest 13F from Sio Capital Management, LLC covers Q2 2026 (filed Aug 14, 2026): 57 long positions worth $583.5M. The top 10 holdings make up 50.1% of the portfolio, and the largest is Anteris Technologies Global Corp. (AVR) at 9.4%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
14
Est. +$153.7M
Added
10
Est. +$51.9M
Reduced
21
Est. −$142.6M
Sold out
30
Est. −$214.3M

Top 5 holdings

Share of this quarter's portfolio value

  1. AVRAnteris Technologies Global Corp.
    9.4%$54.6MHistory
  2. CORCencora, Inc.
    8.4%$49.1MHistory
  3. MMSMaximus, Inc.
    6.6%$38.5MHistory
  4. ALLOAllogene Therapeutics, Inc.
    4.7%$27.7MHistory
  5. GMEDGlobus Medical Inc
    4.1%$23.8MHistory

Share of portfolio

Top 5 holdings and the other 52 positions, by share of portfolio value

  1. AVR9.4%
  2. COR8.4%
  3. MMS6.6%
  4. ALLO4.7%
  5. GMED4.1%
  6. Other 52 positions66.8%

Biggest buys

New and added positions, by estimated amount bought

  1. ALLOAllogene Therapeutics, Inc.
    +$27.7MNewHistory
  2. GMEDGlobus Medical Inc
    +$23.8MNewHistory
  3. CORCencora, Inc.
    +$20.6MAddedHistory
  4. IDYAIDEAYA Biosciences, Inc.
    +$17.9MNewHistory
  5. CICigna Group
    +$15.9MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AVRAnteris Technologies Global Corp.
    +5.06 pp4.3% → 9.4%History
  2. ALLOAllogene Therapeutics, Inc.
    +4.75 pp0.0% → 4.7%History
  3. GMEDGlobus Medical Inc
    +4.09 pp0.0% → 4.1%History
  4. CORCencora, Inc.
    +3.85 pp4.6% → 8.4%History
  5. IDYAIDEAYA Biosciences, Inc.
    +3.07 pp0.0% → 3.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. ICLRIcon PLC
    −$37.9MReducedHistory
  2. DNTHDianthus Therapeutics, Inc.
    −$30.3MReducedHistory
  3. CORTCorcept Therapeutics Inc
    −$27.2MSold outHistory
  4. LIVNLivaNova PLC
    −$26.8MSold outHistory
  5. EMBCEmbecta Corp.
    −$16.3MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CORTCorcept Therapeutics Inc
    −3.92 pp3.9% → 0.0%History
  2. LIVNLivaNova PLC
    −3.86 pp3.9% → 0.0%History
  3. DNTHDianthus Therapeutics, Inc.
    −3.49 pp4.5% → 1.0%History
  4. WAYWaystar Holding Corp.
    −2.45 pp5.7% → 3.3%History
  5. EMBCEmbecta Corp.
    −2.35 pp2.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$583.5M
−$110.3M (−15.9%) vs. prior quarter
Positions
57
−16 vs. prior quarter
Top 10 concentration
50.1%
Top 10 as share of value
Turnover
32.2%
Q2 2026, one quarter
Average holding period
3.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $693.9M (Q1 2026)

Q1 2021: $478.3MQ2 2021: $368.7MQ3 2021: $310.2MQ4 2021: $328.4MQ1 2022: $248.1MQ2 2022: $253.8MQ3 2022: $234.4MQ4 2022: $187.6MQ1 2023: $202.3MQ2 2023: $282.9MQ3 2023: $323.1MQ4 2023: $388.4MQ1 2024: $287.1MQ2 2024: $265.2MQ3 2024: $223.2MQ4 2024: $355.4MQ1 2025: $330.2MQ2 2025: $249.2MQ3 2025: $395.2MQ4 2025: $603.2MQ1 2026: $693.9MQ2 2026: $583.5M
Q1 2021Q2 2026
13F filings of Sio Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202657$583.5MAVRCORMMSvs. Q1 2026SEC
Q1 2026May 14, 202673$693.9MMMSWAYICLRvs. Q4 2025SEC
Q4 2025Feb 17, 202665$603.2MCELCCISNYvs. Q3 2025SEC
Q3 2025Nov 13, 202551$395.2MMMSCELCSNYvs. Q2 2025SEC
Q2 2025Aug 13, 202549$249.2MMMSIRONGMEDvs. Q1 2025SEC
Q1 2025May 15, 202553$330.2MICLRMMSMRKvs. Q4 2024SEC
Q4 2024Feb 14, 202551$355.4MICLRMMSCIvs. Q3 2024SEC
Q3 2024Nov 14, 202438$223.2MLHTEVAMMSvs. Q2 2024SEC
Q2 2024Aug 14, 202446$265.2MLHTFXZBHvs. Q1 2024SEC
Q1 2024May 15, 202448$287.1MLHCIGMEDvs. Q4 2023SEC
Q4 2023Feb 13, 202439$388.4MMRTXGracell Biotechnologies IncLHvs. Q3 2023SEC
Q3 2023Nov 14, 202352$323.1MLHGMEDGSKvs. Q2 2023SEC
Q2 2023Aug 14, 202341$282.9MGEHCLHCIvs. Q1 2023SEC
Q1 2023May 12, 202344$202.3MCNCCIBCYCvs. Q4 2022SEC
Q4 2022Feb 13, 202341$187.6MMedicus Sciences AcquisitionBCYCCIvs. Q3 2022SEC
Q3 2022Nov 14, 202243$234.4MCORGSKMedicus Sciences Acquisitionvs. Q2 2022SEC
Q2 2022Aug 15, 202259$253.8MCORMedicus Sciences AcquisitionOGNvs. Q1 2022SEC
Q1 2022May 16, 202261$248.1MMedicus Sciences AcquisitionCIMRKvs. Q4 2021SEC
Q4 2021Feb 14, 202267$328.4MCIMedicus Sciences AcquisitionCRISvs. Q3 2021SEC
Q3 2021Nov 15, 202159$310.2MCICRISGLDvs. Q2 2021SEC
Q2 2021Aug 16, 202171$368.7MCRISCISoliton, Inc.vs. Q1 2021SEC
Q1 2021May 14, 202185$478.3MCRISCICAH–SEC

13D and 13G filings

Companies where Sio Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

3 companies, largest stake first.

Companies where Sio Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
SERSerina Therapeutics, Inc.13G6.71%1.00M sharesNewMay 4, 20261 filingMay 4, 2026SEC
AVRAnteris Technologies Global Corp.13G/A5.54%5.38M shares+0.62 ppfrom 4.92%Feb 10, 20255 filingsMay 4, 2026SEC
ALGSAligos Therapeutics, Inc.13G/A5.46%335.9K shares−0.03 ppfrom 5.49%Aug 13, 20252 filingsFeb 11, 2026SEC

Latest filings

44 filings on file made by Sio Capital Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Sio Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
ADGMAdagio Medical Holdings, Inc.Jul 28, 20264:49 PM ET13G/A3.15%699.0K shares−2.93 ppfrom 6.08%Below 5%Jun 30, 2026SEC
PMVPPMV Pharmaceuticals, Inc.Jul 28, 20264:48 PM ET13G/A4.94%2.63M shares−0.83 ppfrom 5.77%Below 5%Jun 30, 2026SEC
SERSerina Therapeutics, Inc.May 4, 20264:15 PM ET13G6.71%1.00M sharesNewMar 31, 2026SEC
AVRAnteris Technologies Global Corp.May 4, 20264:14 PM ET13G/A5.54%5.38M shares+0.62 ppfrom 4.92%Mar 31, 2026SEC
PMVPPMV Pharmaceuticals, Inc.May 4, 20264:14 PM ET13G/A5.77%3.08M shares+0.79 ppfrom 4.98%Mar 31, 2026SEC
ADGMAdagio Medical Holdings, Inc.Feb 11, 20264:39 PM ET13G6.08%1.29M sharesNewDec 31, 2025SEC
ALGSAligos Therapeutics, Inc.Feb 11, 20264:32 PM ET13G/A5.46%335.9K shares−0.03 ppfrom 5.49%Dec 31, 2025SEC
PMVPPMV Pharmaceuticals, Inc.Nov 12, 20258:00 AM ET13G/A4.98%2.64M shares−2.21 ppfrom 7.19%Below 5%Sep 30, 2025SEC
NMTCNeuroone Medical Technologies CorpNov 12, 20258:00 AM ET13G/A4.72%2.36M shares−2.35 ppfrom 7.07%Below 5%Sep 30, 2025SEC
DRUGBright Minds Biosciences Inc.Nov 12, 20258:00 AM ET13G/A2.69%190.8K shares−4.58 ppfrom 7.27%Below 5%Sep 30, 2025SEC
APREAprea Therapeutics, Inc.Nov 12, 20258:00 AM ET13G/A1.93%112.2K shares−3.12 ppfrom 5.05%Below 5%Sep 30, 2025SEC
AVRAnteris Technologies Global Corp.Nov 12, 20258:00 AM ET13G/A4.92%1.77M shares−3.22 ppfrom 8.14%Below 5%Sep 30, 2025SEC
NMTCNeuroone Medical Technologies CorpAug 13, 20252:00 PM ET13G7.07%3.52M sharesNewJun 30, 2025SEC
DRUGBright Minds Biosciences Inc.Aug 13, 20252:00 PM ET13G/A7.27%512.3K shares+0.06 ppfrom 7.21%Jun 30, 2025SEC
PMVPPMV Pharmaceuticals, Inc.Aug 13, 20252:00 PM ET13G/A7.19%3.74M shares0.00 ppfrom 7.19%Jun 30, 2025SEC
APREAprea Therapeutics, Inc.Aug 13, 20252:00 PM ET13G/A5.05%279.4K shares+0.01 ppfrom 5.04%Jun 30, 2025SEC
AVRAnteris Technologies Global Corp.Aug 13, 20252:00 PM ET13G/A8.14%2.93M shares−1.48 ppfrom 9.62%Jun 30, 2025SEC
ALGSAligos Therapeutics, Inc.Aug 13, 20252:00 PM ET13G5.49%355.9K sharesNewJun 30, 2025SEC
VTYXVentyx Biosciences, Inc.Apr 8, 20253:14 PM ET13G/A3.63%2.58M shares−2.09 ppfrom 5.72%Below 5%Mar 31, 2025SEC
VXRTVaxart, Inc.Apr 8, 20253:14 PM ET13G2.45%5.58M shares−2.61 ppfrom 5.06%Below 5%Mar 31, 2025SEC